早期乳腺癌乳房切除术后轻度淋巴水肿患者接受复合减充血疗法疗效的预测因素。

IF 1.6 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Lymphatic research and biology Pub Date : 2024-10-01 Epub Date: 2024-09-04 DOI:10.1089/lrb.2023.0021
Ju Hyeon Kim, Han Eum Choi, Jae Hyun Lee, Young-Joo Sim, Ho Joong Jeong, Ghi Chan Kim
{"title":"早期乳腺癌乳房切除术后轻度淋巴水肿患者接受复合减充血疗法疗效的预测因素。","authors":"Ju Hyeon Kim, Han Eum Choi, Jae Hyun Lee, Young-Joo Sim, Ho Joong Jeong, Ghi Chan Kim","doi":"10.1089/lrb.2023.0021","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background:</i></b> Complex decongestive therapy (CDT) is being used in breast cancer-related lymphedema (BCRL). The degree of initial edema and bioimpedance analysis (BIA) are known to be related with the therapeutic effect of CDT. D-dimer can indirectly reflect lymphangiogenesis because IL-6 regulates D-dimer and vascular endothelial growth factor, which is the most important lymphangiogenic factor. We assessed whether D-dimer could be used for the prediction of therapeutic effect of CDT, as well as BIA and initial edema. <b><i>Methods:</i></b> The participants were patients who took inpatient treatment for BCRL from July 2016 to May 2020. Percent excess volume (PEV) was calculated by dividing the difference in volume of both arms by the edema arm, and the difference in PEV before and after 2 weeks of CDT was defined as the CDT effect. BIA and D-dimer tests were performed before treatment. <b><i>Results:</i></b> The single frequency bioimpedance analysis (SFBIA) ratio and D-dimer showed significant correlations with β coefficients of 0.581 and 0.402 (<i>p</i> < 0.01), respectively, and the explanatory power of these models was confirmed to be 0.704.The areas under the curve of initial PEV, SFBIA ratio, D-dimer for determining the CDT effect were identified as 0.849, 0.795, and 0.725, respectively. <b><i>Conclusions:</i></b> Initial PEV, SFBIA ratio, and blood D-dimer levels could be used as predictors for CDT treatment effect. Their usefulness order was in the order of initial PEV, SFBIA ratio, and D-dimer. These factors could be used as predictors to establish therapeutic plan in patients with mild lymphedema.</p>","PeriodicalId":18168,"journal":{"name":"Lymphatic research and biology","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Factors Predicting the Effect of a Complex Decongestive Therapy in Patients with Mild Lymphedema Following Mastectomy for Early Stage Breast Cancer.\",\"authors\":\"Ju Hyeon Kim, Han Eum Choi, Jae Hyun Lee, Young-Joo Sim, Ho Joong Jeong, Ghi Chan Kim\",\"doi\":\"10.1089/lrb.2023.0021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Background:</i></b> Complex decongestive therapy (CDT) is being used in breast cancer-related lymphedema (BCRL). The degree of initial edema and bioimpedance analysis (BIA) are known to be related with the therapeutic effect of CDT. D-dimer can indirectly reflect lymphangiogenesis because IL-6 regulates D-dimer and vascular endothelial growth factor, which is the most important lymphangiogenic factor. We assessed whether D-dimer could be used for the prediction of therapeutic effect of CDT, as well as BIA and initial edema. <b><i>Methods:</i></b> The participants were patients who took inpatient treatment for BCRL from July 2016 to May 2020. Percent excess volume (PEV) was calculated by dividing the difference in volume of both arms by the edema arm, and the difference in PEV before and after 2 weeks of CDT was defined as the CDT effect. BIA and D-dimer tests were performed before treatment. <b><i>Results:</i></b> The single frequency bioimpedance analysis (SFBIA) ratio and D-dimer showed significant correlations with β coefficients of 0.581 and 0.402 (<i>p</i> < 0.01), respectively, and the explanatory power of these models was confirmed to be 0.704.The areas under the curve of initial PEV, SFBIA ratio, D-dimer for determining the CDT effect were identified as 0.849, 0.795, and 0.725, respectively. <b><i>Conclusions:</i></b> Initial PEV, SFBIA ratio, and blood D-dimer levels could be used as predictors for CDT treatment effect. Their usefulness order was in the order of initial PEV, SFBIA ratio, and D-dimer. These factors could be used as predictors to establish therapeutic plan in patients with mild lymphedema.</p>\",\"PeriodicalId\":18168,\"journal\":{\"name\":\"Lymphatic research and biology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lymphatic research and biology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/lrb.2023.0021\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/4 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lymphatic research and biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/lrb.2023.0021","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:复方去充血疗法(CDT)被用于治疗乳腺癌相关淋巴水肿(BCRL)。已知初始水肿程度和生物阻抗分析(BIA)与 CDT 的治疗效果有关。D 二聚体可间接反映淋巴管生成,因为 IL-6 可调节 D 二聚体和血管内皮生长因子,而后者是最重要的淋巴管生成因子。我们评估了 D-二聚体是否可用于预测 CDT 的疗效以及 BIA 和初始水肿。研究方法参与者为 2016 年 7 月至 2020 年 5 月接受 BCRL 住院治疗的患者。用两臂的体积差除以水肿臂,计算出多余体积百分比(PEV),并将 CDT 2 周前后的 PEV 差值定义为 CDT 效果。治疗前进行 BIA 和 D-二聚体检测。结果单频生物阻抗分析(SFBIA)比值和 D-二聚体显示出显著的相关性,β系数分别为 0.581 和 0.402(P < 0.01),这些模型的解释力被证实为 0.704,确定 CDT 效果的初始 PEV、SFBIA 比值、D-二聚体的曲线下面积分别为 0.849、0.795 和 0.725。结论初始 PEV、SFBIA 比值和血 D-二聚体水平可作为 CDT 治疗效果的预测指标。其有用性顺序依次为初始 PEV、SFBIA 比值和 D-二聚体。这些因素可作为轻度淋巴水肿患者制定治疗方案的预测指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Factors Predicting the Effect of a Complex Decongestive Therapy in Patients with Mild Lymphedema Following Mastectomy for Early Stage Breast Cancer.

Background: Complex decongestive therapy (CDT) is being used in breast cancer-related lymphedema (BCRL). The degree of initial edema and bioimpedance analysis (BIA) are known to be related with the therapeutic effect of CDT. D-dimer can indirectly reflect lymphangiogenesis because IL-6 regulates D-dimer and vascular endothelial growth factor, which is the most important lymphangiogenic factor. We assessed whether D-dimer could be used for the prediction of therapeutic effect of CDT, as well as BIA and initial edema. Methods: The participants were patients who took inpatient treatment for BCRL from July 2016 to May 2020. Percent excess volume (PEV) was calculated by dividing the difference in volume of both arms by the edema arm, and the difference in PEV before and after 2 weeks of CDT was defined as the CDT effect. BIA and D-dimer tests were performed before treatment. Results: The single frequency bioimpedance analysis (SFBIA) ratio and D-dimer showed significant correlations with β coefficients of 0.581 and 0.402 (p < 0.01), respectively, and the explanatory power of these models was confirmed to be 0.704.The areas under the curve of initial PEV, SFBIA ratio, D-dimer for determining the CDT effect were identified as 0.849, 0.795, and 0.725, respectively. Conclusions: Initial PEV, SFBIA ratio, and blood D-dimer levels could be used as predictors for CDT treatment effect. Their usefulness order was in the order of initial PEV, SFBIA ratio, and D-dimer. These factors could be used as predictors to establish therapeutic plan in patients with mild lymphedema.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Lymphatic research and biology
Lymphatic research and biology Medicine-Cardiology and Cardiovascular Medicine
CiteScore
3.10
自引率
7.10%
发文量
85
审稿时长
>12 weeks
期刊介绍: Lymphatic Research and Biology delivers the most current peer-reviewed advances and developments in lymphatic biology and pathology from the world’s leading biomedical investigators. The Journal provides original research from a broad range of investigative disciplines, including genetics, biochemistry and biophysics, cellular and molecular biology, physiology and pharmacology, anatomy, developmental biology, and pathology. Lymphatic Research and Biology coverage includes: -Vasculogenesis and angiogenesis -Genetics of lymphatic disorders -Human lymphatic disease, including lymphatic insufficiency and associated vascular anomalies -Physiology of intestinal fluid and protein balance -Immunosurveillance and immune cell trafficking -Tumor biology and metastasis -Pharmacology -Lymphatic imaging -Endothelial and smooth muscle cell biology -Inflammation, infection, and autoimmune disease
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信